which relied more heavily on private funding with out-ofpocket expenses for patients. Early detection and management of kidney disease were least likely to be covered by funding models. The perceived quality of health infrastructure supporting AKI and chronic kidney disease care was rated poor to extremely poor in none of the highincome countries but was rated poor to extremely poor in over 40% of low-income countries, particularly Africa. This study demonstrated significant gaps in oversight, funding, and infrastructure supporting health services caring for patients with kidney disease, especially in low-and middleincome countries. H ealth system oversight and financing are key determinants of the quality, efficiency, and equity of health care delivery. 1 Beyond overseeing the routine functioning and performance of health services, oversight is critical to their strategic development, regulation, and accountability. It shapes the capacity of health systems to develop and implement policies, identify and correct service deficiencies, advocate for health care in national development, and collaborate with stakeholders. Governance bodies should seek to achieve universal health coverage, which requires robust health financing systems. [2] [3] [4] In addition to generating sufficient funds to support the health system, financing systems must allow central pooling of funds for financial risk protection and facilitate equitable allocation of resources to areas of greatest need. Due to differences in infrastructure and economy, significant global variability is expected in health system oversight and financing. In low-income countries, government contributions are less likely to be sufficient to fund health care, creating reliance on supplemental funding from external sources, including nongovernmental organizations (NGOs), community organizations, and private health insurance. Despite these contributions, resources may remain insufficient to ensure financial risk protection, and the monetary burden may be transferred to patients. 5 Lack of resources also compromises the adequacy of health service infrastructure and leads to low-quality health care delivery. 6 The escalating prevalence and associated cost of kidney disease mandates a complete understanding of existing oversight and financing systems to drive effective, efficient, and sustainable service delivery. As the oversight and financing of health services caring for patients with kidney disease have not been previously reported, the present study was performed to examine health system oversight, financing, and infrastructural quality for delivering kidney care across International Society of Nephrology (ISN) regions 7 and 2014 World Bank country classification as low-, lower middle-, upper middle-, and high-income nations. 8 
RESULTS
Of the 130 countries surveyed, 125 countries participated (comprising 93% of the world's population) and 122 countries provided data pertaining to health system oversight and financing (97% response rate).
Health system oversight
Health system oversight of kidney care was performed by a national body in the majority of countries (n ¼ 80, 66%). The highest proportions were reported from North and East Asia (n ¼ 6, 100%) and Latin America and the Caribbean (n ¼ 13, 81%) ( Figure 1a ). There were no appreciable differences in the frequencies of national oversight of kidney care between high-, upper middle-, lower middle-, and low-income countries ( Figure 1b ). Kidney care was managed at a provincial or regional level in 30% (n ¼ 37) of countries and by NGOs in 15% of countries (n ¼ 18). Oversight by NGOs was particularly common in low-income countries and in Oceania and Southeast Asia. Approximately one-half of countries (n ¼ 62, 51%) relied on individual hospitals, trusts, or organizations to oversee governance. This approach was most common in low-income countries. Six percent (n ¼ 7) of countries had no organized system for managing kidney care.
Health system financing Only 19% (n ¼ 23) of countries reported that their health system was publicly funded by government with no fees at the point of delivery (Table 1 ). An additional 24% (n ¼ 28) of countries publicly funded their health system, but with fees at point of delivery. This approach was particularly common for low-income countries (n ¼ 7, 41%). Nearly one-half (n ¼ 52, 44%) of countries reported a mix of public and private funding, especially among high-income countries. Health systems of 13% (n ¼ 16) of countries were funded through multiple sources, including government, NGOs, and community organizations. All residents were eligible for health coverage in more than one-half of respondent countries (n ¼ 69, 58%). This proportion was similar across income groups. Newly Independent States (of the former Soviet Union) and Russian (5 of 6, 83%) countries had the highest rates of health coverage to their residents, while South Asian (2 of 5, 40%) countries had the lowest rates (Table 1) .
Overall, in a publicly funded health care system, the majority of high-income countries publically financed all aspects of kidney care including dialysis, transplantation, management of chronic kidney disease (CKD) complications, management to reduce risk of CKD progression, early detection in individuals at risk, and management of acute kidney injury (AKI) ( Table 2 ). Thirteen percent (n ¼ 2) of low-, 19% (n ¼ 6) of lower middle-, 40% (n ¼ 12) of upper middle-, and 54% (n ¼ 19) of high-income countries funded all aspects of kidney care.
Nondialysis CKD funding. Care for patients with nondialysis CKD was primarily funded by a mixture of public and private sources (n ¼ 61, 51%). Publicly funded care that was free at the point of delivery was overall less common for nondialysis CKD than for any of the other types of kidney care (AKI, dialysis, kidney transplantation) (Table 2, Figure 2a and b). Lower income countries more frequently relied on solely private funding for nondialysis CKD care ( Figure 2b ). Countries in Eastern and Central Europe (n ¼ 12, 75%) had the highest rate of free, publicly funded care for patients with nondialysis CKD, and Oceanian and Southeast Asian countries (n ¼ 3, 23%) had the lowest. Early detection of kidney disease in high-risk individuals was often excluded from public funding (n ¼ 58, 50%) (Table 3) . Similarly, early management to reduce the risk of CKD progression was frequently not covered (n ¼ 47, 40%), nor was general CKD management (n ¼ 46, 39%) or management of CKD complications (e.g., anemia, bone disease, malnutrition) (n ¼ 46, 39%) ( Table 3 ). Dialysis funding. Across all countries, dialysis was primarily funded by government with no fees to patients at the point of delivery (n ¼ 77, 63%) ( Table 2 ). Countries in Newly Independent States and Russia (n ¼ 6, 100%) had the highest rate of free, publicly funded care for patients requiring dialysis, while Oceanian and Southeast Asian countries (n ¼ 4, 31%) had the lowest. Compared with high-income countries, low-income countries were more likely to require financial contribution from patients at the point of service delivery in addition to government funding ( Figure 2b ).
Kidney transplantation funding. Kidney transplantation was publicly funded with no out-of-pocket fees in 57% of countries ( Table 2 ). Countries in Eastern and Central Europe (n ¼ 16, 94%) had the highest rate of free, publicly funded care for patients requiring kidney transplantation, while South Asian countries (n ¼ 1, 25%) had the lowest. The proportion of countries with public funding for kidney transplantation was significantly greater for high-income countries (n ¼ 31, 79%) than for low-income countries (n ¼ 2, 17%). Low-income countries (n ¼ 8, 67%) had the highest proportion of solely private and out-of-pocket funding for kidney transplantation.
AKI funding. Funding for care of patients with AKI was predominantly from public sources ( Table 2 ). Countries in Eastern and Central Europe (n ¼ 16, 94%) had the highest rates of free, publicly funded care for patients with AKI, while South Asian countries (n ¼ 1, 25%) had the lowest. Lowincome countries were more likely to require either a financial contribution from patients in addition to government funding or solely private funding from patients.
Health care infrastructure for CKD/AKI care Overall, 45% of countries (n ¼ 55) reported at least good or above average infrastructure for CKD care, and 48% of countries (n ¼ 59) reported at least good or above average infrastructure for AKI care (Figure 3a ). Countries in Western Europe had the highest rates of perceived above average or excellent infrastructures for CKD and AKI care, while African countries had the lowest (Figure 3a ). The majority of highincome countries rated the quality of their CKD and AKI infrastructures as above average or excellent ( Figure 3b ). The quality of health infrastructures supporting AKI and CKD care were rated poor to extremely poor in none of high-income countries but in over 40% of low-income countries (Figure 3b ).
Within-country kidney care variation
More than one-half of the surveyed countries (n ¼ 80, 66%) reported clinically important variations in kidney care delivery among different regions, states, or provinces within their countries. These variations were particularly prominent in low-(n ¼ 15, 88%) and lower middle-(n ¼ 32, 91%) income countries. Among ISN regions, South Asian countries (n ¼ 5, 100%) had the highest reported within-country kidney care variation, followed by African countries (n ¼ 30, 88%). Eastern (Table 4) .
DISCUSSION
This study identified important variability in health system oversight, financing, and infrastructural quality for kidney care across ISN regions and World Bank income groups, as well as across regions, states, or provinces within countries.
Overall, health systems were most frequently governed by national bodies. Oversight was fragmented in low-income countries, with individual hospitals, trusts, or organizations providing their own oversight. Provincial, regional, or state oversight was more common in high-income countries. Government funding was available for dialysis in all income groups but was associated with additional out-of-pocket expenses to patients in low-income countries. Kidney transplantation was also generally funded privately in low-income countries. Care for patients with nondialysis CKD and AKI was publicly funded in high-income countries and privately funded in low-income countries. Nondialysis CKD care, including early detection and management, was less likely to be publicly funded and free at the point of delivery, than were AKI, dialysis, and kidney transplant care. Universal health coverage-equal access to all required health services by the public without enduring financial burden 9 -was available in only a minority of countries. Infrastructures for CKD and AKI care were rated as above average or excellent in most high-income countries and as extremely poor or below average in most low-income countries. Many challenges relating to health service oversight, funding, and infrastructure have been highlighted in this study. Despite knowledge of the importance of leadership in improving health outcomes, governance of kidney care differed greatly between countries. National oversight of patient care is most suited to containing health care costs and promoting equity and efficiency in resource allocation 10, 11 and is particularly important in resource-poor settings because policies must clearly define patient eligibility for restricted therapy options, including dialysis. Similarly, robust legal frameworks are required, ideally at a national level, prior to establishment of transplantation programs. Lack of such frameworks leads to complex ethical issues, and in some cases may facilitate corrupt practices such as commercial organ trafficking and transplant tourism. 12 Other issues included countries reporting the presence of more than 1 governing body for kidney care, which hindered the ability to exercise overall stewardship. 6 Marked variations in health financing between Word Bank income groups and ISN regions were also identified. In contrast to the World Health Organization recommendations for good service delivery, 6, 13 universal health coverage was not available in a significant proportion of countries, especially low-income countries and those in South Asia and Africa. Provision of universal health coverage is dependent on well-functioning health-financing systems. In high-income countries, prepayment schemes (e.g., taxes and insurance premiums) are frequently employed as a means to pool funds. However, similar systems in low-income countries would be unlikely to be successful due to differences in employment rates and financial security. Furthermore, the frequent need for patients in low-income countries to pay out of pocket at the point of service delivery effectively excluded many patients from accessing kidney care. This is evidenced by the fact that despite a high prevalence of end-stage renal disease (ESRD), relatively few patients receive renal replacement therapy in low-income countries. For example, <10% of Indian patients with ESRD receive renal replacement therapy, and as many as 70% of those starting dialysis die or stop treatment due to cost within the first 3 months. 14 
In a South
African study, less than one-half of patients with ESRD were offered dialysis. 15 Finally, a recently published systematic review of worldwide access to treatment for ESRD based on prevalence data from 123 countries estimated that between 47% and 73% of people with ESRD needing renal replacement therapy actually received it. 16 This figure fell to 9% to 16% in Africa and 1% to 3% in middle and Eastern Africa. 16 Of concern, a substantial proportion of countries did not publicly fund the early detection or prevention of progression of kidney disease in individuals at risk. Despite the financial burden of treating advanced kidney disease, few low-income countries publicly funded early kidney disease detection. 16, 17 Screening for kidney disease in high-risk individuals 18 is considered to be cost-effective [19] [20] [21] [22] [23] and beneficial to public health. 24 Therefore, consideration should be given to channeling resources into establishing and maintaining kidney disease screening programs in individuals at risk. 25 Programs aimed at preventing progression of kidney disease should equally be a priority given the limited access to renal replacement therapy in low-income countries. Although data on the cost effectiveness of CKD prevention are not available, it would seem likely that prevention in the form of an integrated strategy targeting vascular disease and diabetes mellitus would be beneficial.
Development and maintenance of infrastructure is essential to support health system growth and development. 26 For instance, even with appropriate health system oversight and financing, the absence of sufficient infrastructure will restrict growth of dialysis and transplantation. Unfortunately, the scope of this study did not examine each component of infrastructure quality, such as institutional capacity, physical infrastructure, telecommunication, and health information technology use. 13, 26, 27 It is therefore not possible to detail specific shortcomings that affected health care infrastructure ratings. Detailed knowledge of these domains of infrastructure will be critical to targeting initiatives to improve the quality of infrastructure for AKI and CKD patient care. This is the largest, most comprehensive and most up-to-date study of health systems oversight, financing, and infrastructure across countries and regions. Its strengths include high external validity (involving 122 countries with broad coverage across World Bank income groups and geographic regions), use of a rigorous survey instrument based on the widely applied World Health Organization health system building blocks, 13 and involvement of a broad range of key regional and national stakeholders (including nephrologist leaders, health care policymakers, and consumer representative organizations). Follow-up was conducted with ISN regional leaders to resolve any data discrepancies. Lastly, triangulation of data with published literature and gray sources of information (government reports and other sources provided by survey respondents) was used for validation.
These strengths should be balanced against the study's limitations, including response biases such as social desirability bias and demand characteristics. Such biases were mitigated by corroboration and validation of findings with regional leaders and published and gray literature at country levels. The nature of the survey also meant that the information acquired depended largely on the knowledge, expertise, and perceptions of respondents. Some aspects of the survey, such as the rating of infrastructural quality for kidney care, were subjective and therefore a matter of opinion. While the study's assessment of the characteristics of good service delivery was based on the World Health Organization building blocks of health systems, 13 some characteristics, such as continuity, person-centeredness, accountability, and efficiency, were not assessed. Finally, the study was not able to assess in detail the degree and nature of within-country variations in health system oversight, financing, and infrastructure.
In conclusion, this study demonstrated significant heterogeneity in health system oversight and financing across World Bank income groups and ISN regions. Deficiencies in the existing oversight and financing systems, as well as in the infrastructure supporting care for patients with kidney disease are likely to become progressively more significant in the context of increasing strain on financial resources resulting from the rising global prevalence of kidney disease. Governance systems should manage resources in ways that strengthen national health systems and promote universal health coverage. Several international programs have already been established in response to global inequities in access to treatment. 28, 29 However, the success of such strategies may be undermined by inadequate governance systems and health financing. The findings of this study can provide important baseline information against which country progress can be benchmarked.
MATERIALS AND METHODS Study design and participants
The Global Kidney Health Atlas was a multinational, cross-sectional survey conducted by the ISN to evaluate the global capacity and readiness for kidney care. The survey was carried out with a specific focus on 130 countries with ISN affiliate societies, through the ISN's 10 regional boards (Africa, Eastern and Central Europe, Latin America and the Caribbean, Middle East, North America, North and East Asia, Oceania and Southeast Asia, Newly Independent States and Russia, South Asia, and Western Europe). The design, validation, distribution, and analysis of the survey have been previously reported. 30, 31 r e v i e w r e v i e w
As part of the survey, health system oversight, financing, and perceived adequacy of infrastructure were assessed. Survey respondents were asked to identify the organization responsible for oversight of health services caring for patients with kidney disease. These organizations included national bodies; provincial-, regional-, or state-level authorities; individual hospitals, trusts, or organizations; and NGOs. Respondents could also specify the absence of an organized oversight system.
Health system financing models were categorized as either public (i.e., government [national, provincial, state, regional, local]), or private (i.e., family or personal, corporate or for profit, charity, NGOs, and small business or entrepreneurial). 32 terms were used to further delineate funding types: publicly funded by government and free at point of delivery; publicly funded by government but with fees at point of delivery; a mixture of publicly funded (whether or not publicly funded component is free at point of delivery) and private systems; solely private and out of pocket; and multiple systems (i.e., programs provided by government, NGOs, and communities). For "mixed funding," survey respondents were given the option to expand on this answer by adding an open-ended response to explain in more detail the formation of the health care system coverage. The survey also asked whether universal health coverage was available to all of a country's residents. Universal health coverage was defined as access by all residents to all aspects of health services, including promotive, preventive, rehabilitative, and palliative care, without additional costs to patients. 6 Survey respondents had the opportunity to add an open-ended response to provide further explanation. 30 As well as examining the financing structure of the health system, the survey also explored funding models for dialysis, kidney transplantation, nondialysis CKD, and AKI independently. It also addressed funding availability for early detection of CKD in highrisk individuals and prevention of CKD progression through risk factor control.
To assess the perceived adequacy of infrastructure supporting the care of patients with CKD and AKI, respondents were asked to rate the quality of the available services as extremely poor, poor or below average, fair or average, good or above average, and excellent. 30 Countries were stratified by ISN regions 7 and 2014 World Bank country classification as low-, lower middle-, upper middle-, and high-income nations. 8 
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